In hypertension and hyperglycaemia, activated PARP1 can cause vascular endothelial damage.12 Additionally, decreasing the activity of PARP1 in atherosclerosis can attenuate the development of atherosclerotic plaques, enhance the stability of plaques and promote pre‐established atherosclerotic plaque regression.13 In animal models, the pharmacological inhibition of PARP1 or its gene deletion can reduce tissue damage associated with myocardial ischaemia‐reperfusion.14, 15 In addition, PARP1 inhibitors can also reverse the pattern of cell death from necrosis to apoptosis. The gene discussed is PARP1; the disease is hypertensive disorder.